Researching pathogenic parasites can be difficult due to strict laboratory requirements and the risk of infection. LEXSY can be used to investigate kinetoplastids in a safe and convenient way.
The eukaryotic expression system LEXSY has become popular with researchers of kinetoplastid parasites in recent years. Its classification as an S1 organism makes it a valuable and safe tool for parasite research. LEXSY has been successfully used to produce kinetoplastid antigens, investigate the interactions between parasite and host cells and has been tested as a live vaccine against other pathogenic Leishmania species.
Furthermore, the LEXSY expression architecture can also be used in pathogenic Leishmania species and has e.g. been employed to study resistance development to antileishmanial drugs (Figure 1).
Figure 1: Venn diagrams showing up- and downregulated genes in Leishmania mutants resistant to the antileishmanial agents amphotericin B (A), miltefosine (M), paromomycin (P) and antimonials (S). Data was collected from different Leishmania strains using LEXSY architecture. From Rastrojo et al. (2019).
 Ferrer et al. (2019) Production of Recombinant Trypanosoma cruzi Antigens in Leishmania tarentolae. Methods Mol. Biol. 1955:105.
 Geroldinger et al. (2019) Techniques to study phagocytosis and uptake of Leishmania tarentolae by J774 macrophages. Exp. Parasitol. 197:57.
 Nasiri et al. (2016) Immunogenicity and Efficacy of Live L. tarentolae Expressing KMP11-NTGP96-GFP Fusion as a Vaccine Candidate against Experimental Visceral Leishmaniasis Caused by L. infantum. Iran. J. Parasitol. 11:144.
 Rastrojo et al. (2018) Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs. Int. J. Parasitol. Drugs Drug Resist. 8:246.